Sugi Predict

Sugi Predict / Compounds / SCHEMBL554789

SCHEMBL554789

SCHEMBL554789

CC(O)OC(=O)c1ccccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.60
▸ TSHR P16473 2/20 0.60
▸ HPGD P15428 8/20 0.52
▸ HSD17B10 Q99714 5/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ TDP1 Q9NUW8 2/20 0.50
▸ ALDH1A1 P00352 9/20 0.49
▸ KDM4E B2RXH2 8/20 0.49
▸ CA12 O43570 4/20 0.48
▸ CA1 P00915 4/20 0.48
▸ CA2 P00918 4/20 0.48
▸ CA7 P43166 4/20 0.48
▸ CA9 Q16790 4/20 0.48
▸ CA14 Q9ULX7 4/20 0.48
▸ HMGB1 P09429 1/20 0.47
▸ CA4 P22748 1/20 0.47
▸ CA6 P23280 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ NAPRT Q6XQN6 1/20 0.47
▸ ADRB2 P07550 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL27682257 0.98 LMNA (0.58) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL159455 0.88 TSHR (0.53) LMNATSHRHPGDHSD17B10TDP1
SCHEMBL39139 0.86 CA12 (0.66) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL29677974 0.86 CA12 (0.66) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL27897018 0.85 CA12 (0.63) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL3026390 0.83 LMNA (0.58) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL28178978 0.83 LMNA (0.58) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL28810420 0.83 LMNA (0.58) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL5195832 0.83 LMNA (0.58) LMNATSHRHPGDHSD17B10ALOX15
SCHEMBL28178028 0.83 LMNA (0.58) LMNATSHRHPGDHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109475120-B Antimicrobial compositions 西姆莱斯股份公司 2022-03-29 — — CN claimed
EP-3616756-B1 COMPOSITION FOR PROMOTING HAIR GROWTH, USE OF THE HAIR GROWTH AGENT AND METHOD FOR PRODUCING THE SAME MUELLER KAEHMANN DIETER KLAUS (DE) 2022-03-09 — — EP claimed
US-8323684-B2 Water vapor and air permeable elastic backing layer, a matrix layer and permeation enhancers LTS LOHMANN THERAPIE-SYSTEME AG (DE) 2012-12-04 — — US claimed
US-8026285-B2 Control release of biologically active compounds from multi-armed oligomers BEZWADA BIOMEDICAL, LLC (US) 2011-09-27 — — US claimed
US-20110026118-A1 DIFFRACTIVE OPTICAL ELEMENT AND USE OF AN OPTICAL ADHESIVE FOR PRODUCING THE SAME CARL ZEISS AG (DE) 2011-02-03 — — US claimed
US-7691364-B2 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2010-04-06 — — US claimed
US-20090076174-A1 CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS BEZWADA BIOMEDICAL, LLC (US) 2009-03-19 — — US claimed
US-7316657-B2 Massage appliance with adjustable massage characteristics and storage container BEIERSDORF AG (DE) 2008-01-08 — — US claimed
EP-1284718-B1 OCCLUSIVE TRANSDERMAL THERAPEUTIC SYSTEM WIT A NON-OCCLUSIVE BACKING LAYER LOHMANN THERAPIE SYST LTS (DE) 2006-03-29 — — EP claimed
US-6995203-B2 Flame retardant polymer compositions THE BOEING COMPANY (US) 2006-02-07 — — US claimed
US-20050049338-A1 Flame retardant polymer compositions BOEING COMPANY, THE 2005-03-03 — — US claimed
EP-1178783-B1 DEVICE AND USE FOR INCREASING THE TRANSDERMAL PERMEATION OF MEDICAMENTS LOHMANN THERAPIE SYST LTS (DE) 2004-04-21 — — EP claimed
US-20030133970-A1 Occlusive transdermal therapeutic system with a non-occlusive backing layer LTS LOHMANN THERAPIE-SYSTEME AG (DE) 2003-07-17 — — US claimed
CN-1354740-A Pharmaceutical compounds NICOX SA (FR) 2002-06-19 — — CN claimed
US-6261687-B1 BLEND CONTAINING CHELATED METAL OXIDE RELIANCE ELECTRIC TECHNOLOGIES, LLC 2001-07-17 — — US claimed
EP-0814776-B1 TOPICALLY APPLIED PHARMACEUTICAL COMPOSITION, METHOD OF PREPARING IT AND ITS USE GEBRO PHARMA GMBH (AT) 2001-07-04 — — EP claimed
US-6224979-B1 INSULATING RESIN WITH CORONA RESISTANCE IN ELECTRICAL MOTORS, POLYMERIZATION MATERIAL AND A POLYCONDENSATION PRODUCT OF A PARTIALLY HYDROLYZED CHELATED METAL OXIDE PRECURSOR. RELIANCE ELECTRIC TECHNOLOGIES, LLC 2001-05-01 — — US claimed
US-6169119-B1 METAL OXIDE PRECURSOR AND MULTIFUNCTIONAL COMPOUND TO PROVIDE A CHELATED METAL OXIDE PRECURSOR, LOW VISCOSITY MATERIALS AND WHICH CAN LEAD TO THE CREATION OF TRANSPARENT RESINS SUSCEPTIBLE TO PHOTOCURING PROCESSES, FILLERS, INCORPORATED RELIANCE ELECTRIC TECHNOLOGIES, LLC 2001-01-02 — — US claimed
US-5962608-A LIQUID PHASE; HYDROLYSIS OF AN ORGANOMETALLIC COMPOUND RELIANCE ELECTRIC INDUSTRIAL CO. (US) 1999-10-05 — — US claimed
US-5894019-A Topically applied pharmaceutical composition, method of preparing it and its use GEBRO BROSCHEK GESELLSCHAFT M.B.H. (AT) 1999-04-13 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076174-A1 CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS MME, CTSA, ALG1 LMNA 970/4885TSHR 3963/4885HPGD 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.